TENOFOVIR DISOPROXIL fumarate 300mg, eq. 245mg base, tab.
STD
DORATENO3T-
Valid Article
Account code:
60000
HS Code:
300490
Last Updated on:
07/11/2024, 20:40:01
Former
Code(s):
-X DORAZBD0426
6.4.2.1 - Nucleoside/Nucleotide reverse transcriptase inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.4.4.1.1 - Nucleoside/Nucleotide reverse transcriptase inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AF07
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
TENOFOVIR (TDF)
Therapeutic Action
Antiretroviral, nucleotide reverse transcriptase inhibitor (NRTI)
Indications
Chronic hepatitis B virus (HBV) infection in adults and children from 12 years of age.
For HIV treatment, use fixed-dose combination containing tenofovir, in combination with other ARVs.
Instructions for use
300 mg tenofovir fumarate is equivalent to 245 mg tenofovir base.
Entecavir (ETV), another antiretroviral NRTI, is recommended as first-line treatment for chronic hepatitis B virus infection in children aged 2 to 12 years.
Fixed-dose combinations of TDF/3TC (lamivudine) or TDF/FTC (emtricitabine) are recommended as alternative regimens where TDF monotherapy is not available.
Precautions for Use
Closely monitor renal function .
Storage
Below 25ºC